Compare TGTX & LEVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | LEVI |
|---|---|---|
| Founded | 1993 | 1853 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.6B |
| IPO Year | 2008 | 2019 |
| Metric | TGTX | LEVI |
|---|---|---|
| Price | $53.27 | $19.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $69.71 | $27.53 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 11-02-2026 | 10-07-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | ★ 1746.67 | 178.85 |
| EPS | 0.17 | ★ 0.67 |
| Revenue | $2,785,000.00 | ★ $6,282,000,000.00 |
| Revenue This Year | $55.81 | $7.63 |
| Revenue Next Year | $37.36 | $4.85 |
| P/E Ratio | $305.97 | ★ $30.81 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.76 | $17.72 |
| 52 Week High | $59.30 | $25.70 |
| Indicator | TGTX | LEVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 42.35 |
| Support Level | $51.76 | $19.13 |
| Resistance Level | $58.26 | $20.37 |
| Average True Range (ATR) | 2.18 | 0.49 |
| MACD | -0.55 | 0.15 |
| Stochastic Oscillator | 27.90 | 49.67 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.